Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study-Reference-Cited by-同舟云学术

Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study

Published:2016-02-02 Issue:3 Volume:3 Page:200-215
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann Clin Transl Neurol

Author:

Narita Aya¹^ORCID,Shirai Kentarou¹,Itamura Shinji¹,Matsuda Atsue¹,Ishihara Akiko²,Matsushita Kumi²,Fukuda Chisako³,Kubota Norika⁴,Takayama Rumiko⁵,Shigematsu Hideo⁵,Hayashi Anri⁶,Kumada Tomohiro⁶,Yuge Kotaro⁷,Watanabe Yoriko⁷,Kosugi Saori⁸,Nishida Hiroshi⁸,Kimura Yukiko⁸,Endo Yusuke⁹,Higaki Katsumi¹⁰,Nanba Eiji¹⁰,Nishimura Yoko¹,Tamasaki Akiko¹,Togawa Masami¹,Saito Yoshiaki¹,Maegaki Yoshihiro¹,Ohno Kousaku¹,Suzuki Yoshiyuki¹¹

Affiliation:

1. Division of Child Neurology Institute of Neurological Science Tottori University Faculty of Medicine Yonago Japan

2. Rehabilitation Division Tottori University Hospital Yonago Japan

3. Department of Pathobiological Science and Technology Faculty of Medicine Tottori University Yonago Japan

4. Department of Pediatrics National Hospital Organization Matsue Medical Center Shimane Japan

5. Department of Pediatrics National Epilepsy Center Shizuoka Institute of Epilepsy and Neurological Disorders Shizuoka Japan

6. Department of Pediatrics Shiga Medical Center for Children Moriyama Japan

7. Department of Pediatrics and Child Health Kurume University School of Medicine Kurume Japan

8. Pharmacokinetics and Bioanalysis Center Shin Nippon Biomedical Laboratories, Ltd Kainan Japan

9. Center for Promoting Next‐Generation Highly Advanced Medicine Tottori University Hospital Yonago Japan

10. Division of Functional Genomics, Research Center for Bioscience and Technology Tottori University Yonago Japan

11. Tokyo Metropolitan Institute of Medical Science Tokyo Japan

Funder

Ministry of Health, Labor and Welfare of Japan

Publisher

Wiley

Subject

Clinical Neurology,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acn3.292

Reference40 articles.

1. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype

2. Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3

3. Accumulation of Glucosylceramide and Glucosylsphingosine (Psychosine) in Cerebrum and Cerebellum in Infantile and Juvenile Gaucher Disease

4. Phenotype, diagnosis, and treatment of Gaucher's disease

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and preclinical insights into high-dose ambroxol therapy for Gaucher disease type 2 and 3: A comprehensive systematic review;Molecular Genetics and Metabolism;2024-09

2. Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease;Neurochemistry International;2024-09

3. Gaucher disease provides a unique window into Parkinson disease pathogenesis;Nature Reviews Neurology;2024-08-06

4. GBA1-Associated Parkinson’s Disease Is a Distinct Entity;International Journal of Molecular Sciences;2024-06-28

5. Neuronopathic Gaucher disease: Rare in the West, common in the East;Journal of Inherited Metabolic Disease;2024-05-20